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6educed Atrial Fibrillation Incidence by
ngiotensin-Converting Enzyme Inhibitors:
Possible Contributing Mechanism
ith great interest we read the study by L’Allier et al. (1)
egarding a reduced incidence of atrial fibrillation in hypertensive
ubjects treated with angiotensin-converting enzyme (ACE) inhi-
ition. The investigators mention several possible mechanisms
ontributing toward this effect. We and several other groups have
hown that angiotensin I and II facilitate the release of norepi-
ephrine from atrial sympathetic fibers through activation of
rejunctional angiotensin receptors in human and animal models
2–4). This effect is reduced under the influence of angiotensin
eceptor antagonists and ACE inhibitors (5,6). An increase in
ympathetic tone is considered by many researchers as an impor-
ant factor in initiating and maintaining atrial fibrillation (7,8). In
ur view, the facilitative effect of angiotensins on norepinephrine
elease and the inhibition of this effect by ACE inhibitors and
ngiotensin receptor antagonists should be considered as possible
echanisms for the reduced occurrence of atrial fibrillation in
CE-inhibitor–treated patients.
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1). The mechanisms by which angiotensin-converting enzyme
ACE) inhibition exerts its protective effect against development
f atrial fibrillation in the setting of hypertension or heart failure
2) are not completely understood. We have discussed several
ossible contributing mechanisms in our study. In patients with
ongestive heart failure, neurohormonal activation, left ventricular
emodeling, elevated left atrial pressure, and atrial fibrosis probably
nteract to provide a pathophysiologic substrate for atrial fibrilla-
ion, which can be, at least partially, reversible with ACE inhibi-
ion (3,4). Some of these beneficial effects of ACE inhibitors may
lso be relevant for the prevention of atrial fibrillation in patients
ith hypertension (1).
In addition to its favorable role in atrial structural remodeling,
nhibition of angiotensin II also has favorable effects on electro-
hysiologic remodeling by preventing atrial effective refractory
eriod shortening and loss of atrial effective refractory period rate
daptation during rapid pacing (5). Reduction of angiotensin-
ediated norepinephrine release from atrial sympathetic fibers (6)
ay contribute, along with other preventive effects on structural
nd electrophysiologic remodeling, to the reduced occurrence of
trial fibrillation with ACE inhibitor therapy.
Jean-Claude Tardif, MD, FACC
hilippe L. L’Allier, MD
ierre-Frédéric Keller, MD
nique Ducharme, MD
Montreal Heart Institute
esearch Center
000 Belanger Street
ontreal, Quebec
anada H1T 1C8
-mail: jean-claude.tardif@icm-mhi.org
doi:10.1016/j.jacc.2004.12.056
EFERENCES
. L’Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC.
Angiotensin-converting enzyme inhibition in hypertensive patients is
associated with a reduction in the occurrence of atrial fibrillation. J Am
Coll Cardiol 2004;44:159–64.
. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the
incidence of atrial fibrillation in patients with left ventricular dysfunc-
tion. Insight from the Studies Of Left Ventricular Dysfunction
(SOLVD) trials. Circulation 2003;107:2926–31.
. Shi Y, Li D, Tardif JC, et al. Enalapril effects on atrial remodeling and
atrial fibrillation in experimental congestive heart failure. Cardiovasc
Res 2002;54:456–61.
. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting
enzyme inhibition on the development of the atrial fibrillation substrate
in dogs with vetricular tachypacing-induced congestive heart failure.
Circulation 2001;104:2608–14.
. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist
prevents electrical remodeling in atrial fibrillation. Circulation 2000;
101:2612–7.
. El Muayed M, Stegbauer J, Oberhauser V, Vonend O, Rump L. AT1-
and AT2-receptor antagonists inhibit Ang II-mediated facilitation of
noradrenaline release in human atria. J Cardiovasc Pharmacol
2004;43:318–24.
